Skip to main content
Cell & Bioscience logoLink to Cell & Bioscience
. 2023 Feb 9;13:27. doi: 10.1186/s13578-023-00976-x

Retraction Note: The suppressing role of miR-622 in renal cell carcinoma progression by down-regulation of CCL18/MAPK signal pathway

Tian Li 1,2,, Xiangzhou Sun 3, Kewei Xu 4
PMCID: PMC9912637  PMID: 36759851

Retraction to: Cell Biosci (2018) 8:17 https://doi.org/10.1186/s13578-018-0212-8

The Editor-in-Chief has retracted this paper. After publication, concerns were raised around the similarity between the rightmost ACHN panel of Fig. 4f and the TGF-B1 + Celecoxib panel in Fig. 5B in a previously-published article by different authors [1]. The Editor-in-Chief therefore no longer has confidence in the results and conclusions of this article. The authors have not responded to any correspondence from the editor about this retraction.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Reference

  • 1.Cha BK, Kim YS, Hwang KE, Cho KH, Oh SH, Kim BR, Jun HY, Yoon KH, Jeong ET, Kim HR. Celecoxib and sulindac inhibit TGF-β1-induced epithelial-mesenchymal transition and suppress lung cancer migration and invasion via downregulation of sirtuin 1. Oncotarget 2016; 7(35): 57213. 10.18632/oncotarget.11127 [DOI] [PMC free article] [PubMed]

Articles from Cell & Bioscience are provided here courtesy of BMC

RESOURCES